Compare Crescent Energy Company Class A Common Stock (CRGY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crescent Energy Company Class A Common Stock vs Novartis AG — how do they compare? Crescent Energy Company Class A Common Stock trades at $12.66 (market cap $4.30B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 62.5× Crescent Energy Company Class A Common Stock's market cap, and Crescent Energy Company Class A Common Stock pays the higher dividend (3.69%). Which is the better fit depends on your goals — on Pluang, investors hold Crescent Energy Company Class A Common Stock for 1 Days and Novartis AG for 82 Days on average.
| CRGY | NVS | |
|---|---|---|
Market Cap | $4.30B | $268.57B |
Volume | 15,201,625 | 1,532,573 |
Sector | Energy | Health |
52-Week High | $15.37 | $168.62 |
52-Week Low | $7.75 | $121.80 |
Typical Hold Time | 1 Days | 82 Days |
Enterprise Value | $9.31B | $309.89B |
Dividend Yield | 3.69% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crescent Energy Company Class A Common Stock
Crescent Energy acquires, develops, and produces oil and natural gas from onshore U.S. basins. Its portfolio includes producing assets with oil and natural gas exposure.
Read more on CRGY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
